Exservan is owned by Mitsubishi Holdings.
Exservan contains Riluzole.
Exservan has a total of 2 drug patents out of which 0 drug patents have expired.
Exservan was authorised for market use on 22 November, 2019.
Exservan is available in film;oral dosage forms.
The generics of Exservan are possible to be released after 03 April, 2024.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8765167||MITSUBISHI HOLDINGS||Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions|| |
(1 year, 17 days from now)
|US8603514||MITSUBISHI HOLDINGS||Uniform films for rapid dissolve dosage form incorporating taste-masking compositions|| |
(1 year, 1 month from now)
Market Authorisation Date: 22 November, 2019
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic